Adma Biologics Profit Margin

The latest profit margin for ADMA is 32.98% as of June 2026. That compares with 44.06% in the prior-year period — down 25.1% year over year. That is above the Healthcare sector average of 13.76%. Investors often review this figure alongside Adma Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADMA's profit margin moved from 44.06% to 32.98% — a 25.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adma Biologics's valuation or profitability profile.

Against Healthcare companies, ADMA currently prints 32.98% for profit margin, while the sector average sits near 13.76%. That is roughly 139.7% above the sector mean. Large gaps often invite a closer look at Adma Biologics's growth, margins, and balance sheet.

Profit Margin shows how effectively Adma Biologics converts resources into returns. At 32.98%, ADMA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 44.06% in the prior-year period — down 25.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADMA's profit margin (32.98%), review year-over-year change from 44.06%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.